How much does tesamorelin increase HGH? Studies show roughly a 1.5-3x rise in daily GH output and a 0.5-1.0 jump in IGF-1 SDS. See what changes the number.
Tesamorelin typically raises daily growth hormone output by roughly 1.5 to 3 times a person's baseline, and it lifts IGF-1 by about 0.5 to 1.0 standard deviation score (SDS) in most clinical trials. Those figures come from measured hormone levels in treated patients, not from marketing claims. The exact increase varies widely with dose, age, body weight, and how much natural GH the pituitary is still able to release.
What the Clinical Data Actually Show
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. It binds to GHRH receptors in the pituitary and prompts the gland to release its own GH in pulses. Because the drug acts upstream of the pituitary, the size of the bump depends partly on how well that gland still functions.
Across phase 3 trials in adults with HIV-associated lipodystrophy, the 2 mg daily dose produced two consistent changes:
- IGF-1 rose by roughly 0.5 to 1.0 SDS, moving most patients from the lower end of the normal range toward the middle or upper end.
- 24-hour GH secretion increased by about two-fold in pharmacokinetic studies, with individual results ranging from roughly 1.5x to 3x baseline.
Visceral fat, the endpoint used for FDA approval, dropped about 15% after 26 weeks of treatment. That fat loss is a downstream effect of the hormone increase rather than the direct mechanism.
| Measurement | Typical change on 2 mg/day | Notes |
|---|---|---|
| IGF-1 | +0.5 to +1.0 SDS | Most reliable marker; effect builds over 12 to 26 weeks |
| 24-hour GH output | About 1.5x to 3x baseline | GH is pulsatile, so single blood draws are unreliable |
| Visceral fat (CT or MRI) | Roughly -15% at 26 weeks | Primary endpoint in the approval trials |
Why the Increase Differs So Much Between People
Two people can take the same dose and see very different lab results. The biggest drivers are:
- Dose. The approved dose is 2 mg injected subcutaneously once daily. Lower doses produce smaller IGF-1 responses, while higher doses do not necessarily add benefit and can push IGF-1 above the normal range.
- Age and baseline GH. GH production falls naturally with age, so a 60-year-old often starts lower and may see a larger relative jump.
- Body composition. Higher body fat is linked to blunted GH secretion and, in some studies, a weaker response to GHRH stimulation.
- Injection timing and technique. Most protocols dose at night, when natural GH release is already highest. Injecting into scar tissue changes absorption.
- Adherence. Daily use matters. Skipping several days a week flattens the IGF-1 curve.
IGF-1 Is the Number Clinicians Actually Track
Growth hormone is released in bursts, so a random GH level tells you very little. IGF-1 is more stable, has a longer half-life, and reflects average GH activity over the previous day or two. That makes IGF-1 the practical way to measure how much a person's GH output has actually risen.
If you want to understand how does hgh work, the short version is this: the pituitary releases GH into the bloodstream, and the liver converts much of it into IGF-1, which then drives most of the tissue effects. Tesamorelin turns up the first step, and the liver does the rest.
Doctors monitoring tesamorelin therapy generally check IGF-1 at baseline, again after a few weeks, and then periodically. The goal is usually to keep IGF-1 inside the age-adjusted normal range, not to push it as high as possible. Persistently elevated IGF-1 is tied to side effects and is one reason a clinician may lower the dose or stop treatment.
Tesamorelin vs. Injecting HGH Directly
Tesamorelin and somatropin (recombinant HGH) are not interchangeable. One stimulates your own pituitary, and the other replaces the hormone entirely.
| Feature | Tesamorelin | Injectable HGH (somatropin) |
|---|---|---|
| Mechanism | Stimulates pituitary GH release | Delivers exogenous GH directly |
| FDA-approved for | HIV-associated lipodystrophy | Specific GH deficiency and pediatric diagnoses |
| Typical monthly cost | Brand-name Egrifta SV list prices run several thousand dollars | Often $1,000 to $3,000 or more, depending on dose and brand |
| Monitoring | IGF-1 | IGF-1, plus thyroid and glucose labs |
Cost is a major reason people compare the two. If you are weighing options, it helps to know how much does hgh cost through a pharmacy with insurance versus a cash-pay clinic, because the spread is enormous and that price gap is usually larger than the difference in results.
Dosing, Timing, and How Soon It Works
Questions about how much tesamorelin should i take a day usually come back to the labeled 2 mg subcutaneous dose once daily. That is the dose studied in the trials that produced the IGF-1 and visceral fat data. Off-label users sometimes take less, but there is limited evidence that lower doses produce the same effect.
As for how long does tesamorelin take to work: IGF-1 levels often begin rising within one to two weeks, and the full IGF-1 effect typically shows up by 8 to 12 weeks. Changes in visceral fat take longer, and the trials measured them at 26 weeks. Anyone expecting visible results in a few days will be disappointed.
Side Effects and Safety
Tesamorelin is generally tolerated, but it is not risk-free. In trials, the most common issues were injection site reactions, joint pain, muscle pain, swelling, and mild increases in blood sugar.
Because tesamorelin raises IGF-1, it carries a theoretical concern about stimulating tumor growth, and it is contraindicated in people with active cancer. It is not recommended during pregnancy. Anyone with diabetes, thyroid disease, or a history of cancer should talk with a healthcare professional before using it.
One question that comes up often is does tesamorelin increase appetite. Appetite changes were not a consistent finding in the clinical trials, though shifts in fluid balance and blood sugar can leave some people feeling hungrier or more tired than usual.
Regulatory Status and Sourcing
Tesamorelin is FDA-approved only for HIV-associated lipodystrophy and is available by prescription as Egrifta SV. Any use for fat loss, anti-aging, or athletic performance is off-label in the United States.
Research-grade tesamorelin sold online without a prescription is not FDA-approved, and its purity and actual content are not verified. Documentation and third-party testing matter more than a low price when a product is going to be injected.
Tesamorelin usually multiplies daily GH output by roughly 1.5x to 3x and raises IGF-1 by about 0.5 to 1.0 SDS, but the response is individual and should be guided by lab monitoring and a healthcare professional.
Frequently Asked Questions
How much does tesamorelin increase HGH levels?
In clinical trials, the 2 mg daily dose increased 24-hour GH secretion by roughly two-fold, with individual results ranging from about 1.5 to 3 times baseline. IGF-1, the more stable marker, rose by about 0.5 to 1.0 SDS. Age, body weight, and how much natural GH your pituitary still produces all shift the number.
Is tesamorelin the same as HGH?
No. Tesamorelin is a GHRH analog that signals your pituitary to release its own growth hormone, while injectable HGH (somatropin) delivers the hormone directly into the bloodstream. That difference is why tesamorelin results depend on how well your pituitary still functions.
Does tesamorelin work for people who are not HIV-positive?
Published data on tesamorelin in people without HIV-associated lipodystrophy is limited, and the drug is FDA-approved only for that condition, so all other use is off-label. Small studies in healthy older adults have shown IGF-1 increases, but long-term safety in that group is not well established. Talk with a healthcare professional before using it.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.